Cat. No.: HY-76711

Naltrexone

Customer Review

Based on 1 Customer Validation

Naltrexone is an orally active, long-acting opioid receptor (opioid receptor) antagonist. Naltrexone blocks the euphoric effects of exogenous opioids and reduces alcohol craving by blocking opioid receptors (μ, κ, and δ) as well as opioid growth factor receptors. Low doses of Naltrexone are used to relieve chronic pain, treat inflammatory diseases and inhibit tumor growth, while high doses or continuous administration exert pro-inflammatory or pro-proliferative effects. Naltrexone relieves intractable pruritus caused by psoriasis, atopic dermatitis and other conditions, and its combination with Bupropion (HY-B0403) inhibits food craving, thereby reducing body weight.

For research use only. We do not sell to patients.

Purity: 99.82%
CAS No.: 16590-41-3
Formula: C₂₀H₂₃NO₄
Molecular Weight:341.40

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Naltrexone Chemical Structure

CAS No.: 16590-41-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[3]

μ Opioid Receptor/MOR

κ Opioid Receptor/KOR

δ Opioid Receptor/DOR

All Opioid Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
BV-2	IC₅₀	105.5 μM Compound: 31	Inhibition of LPS-induced NO production in mouse BV-2 microglia cells incubated for 24 hrs by 2,3-diaminonaphthalene assay Inhibition of LPS-induced NO production in mouse BV-2 microglia cells incubated for 24 hrs by 2,3-diaminonaphthalene assay	[PMID: 35307617]
CHO	EC₅₀	0.16 nM Compound: NTX	Agonist activity at mouse mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding after 1.5 hrs Agonist activity at mouse mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding after 1.5 hrs	[PMID: 23948248]
CHO	EC₅₀	0.16 nM Compound: NTX	Stimulation of mouse MOR expressed in CHO cells after 1.5 hrs by [35S]GTPgammaS binding assay Stimulation of mouse MOR expressed in CHO cells after 1.5 hrs by [35S]GTPgammaS binding assay	[PMID: 25783191]
CHO	EC₅₀	0.38 nM Compound: NTX	Agonist activity at mu opioid receptor (unknown origin) expressed CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding Agonist activity at mu opioid receptor (unknown origin) expressed CHO cells assessed as stimulation of [35S]-GTP[gammaS] binding	[PMID: 23721804]
CHO	EC₅₀	0.59 K_e/nM Compound: NTX (1)	Stimulation of DAMGO binding in recombinant human Opioid receptor mu 1 transfected into CHO cells Stimulation of DAMGO binding in recombinant human Opioid receptor mu 1 transfected into CHO cells	[PMID: 12672258]
CHO	EC₅₀	0.81 nM Compound: NTX	Agonist activity at kappa opioid receptor (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding after 1.5 hrs Agonist activity at kappa opioid receptor (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding after 1.5 hrs	[PMID: 24144240]
CHO	EC₅₀	0.81 nM Compound: NTX	Agonist activity at mouse KOR expressed in CHO cells after 1.5 hrs by [35S]GTPgammaS binding assay Agonist activity at mouse KOR expressed in CHO cells after 1.5 hrs by [35S]GTPgammaS binding assay	[PMID: 25783191]
CHO	EC₅₀	1.86 K_e/nM Compound: NTX (1)	Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells. Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.	[PMID: 12672258]
CHO	EC₅₀	16 nM Compound: 3, NTRX	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 19282177]
CHO	EC₅₀	21 nM Compound: 3, NTRX	Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding Agonist activity at human delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 19282177]
CHO	EC₅₀	3.3 nM Compound: 3, NTRX	Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 19282177]
CHO	EC₅₀	4.4 nM Compound: NTX	Agonist activity at delta opioid receptor (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding after 1.5 hrs Agonist activity at delta opioid receptor (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]-GTPgammaS binding after 1.5 hrs	[PMID: 24144240]
CHO	EC₅₀	4.4 nM Compound: NTX	Agonist activity at mouse DOR expressed in CHO cells after 1.5 hrs by [35S]GTPgammaS binding assay Agonist activity at mouse DOR expressed in CHO cells after 1.5 hrs by [35S]GTPgammaS binding assay	[PMID: 25783191]
CHO	EC₅₀	5.44 nM Compound: NTX	Agonist activity at human recombinant delta opioid receptor expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay Agonist activity at human recombinant delta opioid receptor expressed in CHO cell membranes after 60 mins by [35S]GTPgammaS binding assay	[PMID: 24973818]
CHO	EC₅₀	5.44 K_e/nM Compound: NTX (1)	Stimulation of [35S]GTP-gamma-S, binding at human recombinant Opioid receptor delta 1 transfected into CHO cells. Stimulation of [35S]GTP-gamma-S, binding at human recombinant Opioid receptor delta 1 transfected into CHO cells.	[PMID: 12672258]
CHO	IC₅₀	0.59 nM Compound: 3d	Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding Activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding	[PMID: 17004724]
CHO	IC₅₀	0.95 nM Compound: NTX	Binding affinity to MOR Y210A mutant (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay Binding affinity to MOR Y210A mutant (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay	[PMID: 24055076]
CHO	IC₅₀	1.86 nM Compound: 3d	Activity at human recombinant kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding Activity at human recombinant kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding	[PMID: 17004724]
CHO	IC₅₀	10.35 nM Compound: NTX	Binding affinity to MOR W318A mutant (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay Binding affinity to MOR W318A mutant (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay	[PMID: 24055076]
CHO	IC₅₀	130 nM Compound: 3, NTRX	Antagonist activity against human delta opioid receptor expressed in CHO cells assessed as inhibition of SNC80-stimulated [35S]GTPgammaS binding Antagonist activity against human delta opioid receptor expressed in CHO cells assessed as inhibition of SNC80-stimulated [35S]GTPgammaS binding	[PMID: 19282177]
CHO	IC₅₀	130 nM Compound: 3, NTRX	Antagonist activity against human kappa opioid receptor expressed in CHO cells assessed as inhibition of U50488-stimulated [35S]GTPgammaS binding Antagonist activity against human kappa opioid receptor expressed in CHO cells assessed as inhibition of U50488-stimulated [35S]GTPgammaS binding	[PMID: 19282177]
CHO	IC₅₀	15.5 nM Compound: NTX	Antagonist activity at human MOR expressed in CHO cells assessed as inhibition of DAMGO-induced increase in intracellular Ca2+ level incubated for 15 mins prior to DAMGO addition by microplate reader analysis Antagonist activity at human MOR expressed in CHO cells assessed as inhibition of DAMGO-induced increase in intracellular Ca2+ level incubated for 15 mins prior to DAMGO addition by microplate reader analysis	[PMID: 25783191]
CHO	IC₅₀	17 nM Compound: 3	Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as inhibition of DAGO-stimulated [35S]GTPgammaS binding Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as inhibition of DAGO-stimulated [35S]GTPgammaS binding	[PMID: 17407276]
CHO	IC₅₀	200 nM Compound: 3	Antagonist activity at human opioid kappa receptor expressed in CHO cells assessed as inhibition of U-50488-stimulated [35S]GTP-gamma-S binding Antagonist activity at human opioid kappa receptor expressed in CHO cells assessed as inhibition of U-50488-stimulated [35S]GTP-gamma-S binding	[PMID: 17407276]
CHO	IC₅₀	3.9 nM Compound: NTX	Binding affinity to wild type MOR (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay Binding affinity to wild type MOR (unknown origin) expressed in CHO cells after 15 mins by Ca2+ mobilization assay	[PMID: 24055076]
CHO	IC₅₀	4.1 nM Compound: 1b	Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells Antagonist activity assessed as inhibition of loperamide-stimulated [35S]GTPgammaS binding to human mu opioid receptor expressed in CHO cells	[PMID: 17149859]
CHO	IC₅₀	4.1 nM Compound: 2b	Antagonist activity against human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding Antagonist activity against human cloned mu opioid receptor expressed in CHO cells assessed as inhibition of loperamide-stimulated [35S]GTP-gamma-S binding	[PMID: 17149858]
CHO	IC₅₀	4.8 nM Compound: 3, NTRX	Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding Antagonist activity against human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding	[PMID: 19282177]
CHO	IC₅₀	5.44 nM Compound: 3d	Activity at human recombinant delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding Activity at human recombinant delta opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding	[PMID: 17004724]
CHO	IC₅₀	8.9 nM Compound: NTX	Antagonist activity at human mu opioid receptor expressed in Gqi5 transfected CHO cells assessed as inhibition of DAMGO-stimulated Ca2+ influx preincubated for 15 mins followed by DAMGO challenge Antagonist activity at human mu opioid receptor expressed in Gqi5 transfected CHO cells assessed as inhibition of DAMGO-stimulated Ca2+ influx preincubated for 15 mins followed by DAMGO challenge	[PMID: 23682308]
HEK293	IC₅₀	157.51 μM Compound: Naltrexone	Inhibition of human OCT1 expressed in HEK293 cells assessed as reduction in ASP+ substrate uptake by microplate reader based analysis Inhibition of human OCT1 expressed in HEK293 cells assessed as reduction in ASP+ substrate uptake by microplate reader based analysis	[PMID: 31597043]

In Vitro

Naltrexone (1-100 μM; 48-120 h) inhibited proliferation of SKOV-3, MDA-MB-231, SK-N-MC, OVCAR-3, MIA PaCa-2, SCC-1, and HCT-116 cancer cells via intermittent or short-term treatment, while continuous treatment stimulated proliferation^[3].
Naltrexone (1.0 mg/mL; 24-72 h) inhibited proliferation of SW480 and HCT116 colon cancer cells in a time-dependent manner, with maximum inhibition at 72 h^[3].
Naltrexone (1 μM) increases the activity of mouse hypothalamic arcuate POMC-EGFP cells in vitro, and this effect is amplified when combined with Bupropion^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:

SKOV-3 human ovarian cancer cells, MDA-MB-231 triple negative breast cancer cells, SK-N-MC human neuroblastoma cells, OVCAR-3 human ovarian carcinoma cells, MIA PaCa-2 human pancreatic carcinoma cells, SCC-1 human squamous carcinoma cells, HCT-116 human colon carcinoma cells
Concentration:

1, 10 and 100 μM
Incubation Time:

48, 72, 96 and 120 h
Result:

Reduced SKOV-3 cell numbers by 42% (10 μM, 120 h intermittent).
Reduced MDA-MB-231 cell numbers by 35% (1 μM, 72 h intermittent).
Reduced SK-N-MC cell numbers by 35% (100 μM, 48 h continuous).
Reduced SKOV-3 cell numbers by 29% (10 μM, 96 h short-term).
Reduced SKOV-3 cell numbers by 32% (10 μM, 72 h short-term).
Reduced OVCAR-3 cell numbers by 28% (10 μM, 72 h short-term).
Reduced MIA PaCa-2 cell numbers by 31% (10 μM, 72 h short-term).
Reduced SCC-1 cell numbers by 26% (10 μM, 72 h short-term).
Reduced HCT-116 cell numbers by 24% (10 μM, 72 h short-term).
Increased cell numbers in multiple cell lines with continuous treatment.

Cell Proliferation Assay^[3]

Cell Line:

SW480 human colon cancer cells, HCT116 human colon cancer cells
Concentration:

1.0 mg/mL
Incubation Time:

24 h, 48 h, 72 h
Result:

Inhibited SW480 cell proliferation by 6% (24 h), 23% (48 h), and 41% (72 h).
Inhibited HCT116 cell proliferation by 16% (24 h), 45% (48 h), and 68% (72 h) relative to control.

In Vivo

Naltrexone (0.1-10 mg/kg; i.p.; 1, 3, 7 times per week) at low-dose administration extends tumorigenesis latency in a frequency-dependent manner, whereas high-dose treatment shortens tumorigenesis latency in mice bearing human squamous cell carcinoma SCC-1^[3].
Naltrexone (0.1 mg/kg; i.p.; daily administration; for 40 consecutive days) reduces the number and weight of tumor nodules in mice bearing SKOV-3 human epithelial ovarian cancer^[3].
Naltrexone (1-75 mg/kg; administered via dietary supplementation or injection; dosing frequency of twice weekly or twice daily; treatment duration of 25 days) reduces the tumor volume and diameter in DMBA (HY-W011845)-induced breast cancer rats, and a higher dose of the injection route results in a greater reduction in tumor diameter^[3].
Naltrexone (0.1-10 mg/kg; intravenous injection; once daily; for 75 consecutive days) at low-dose administration extend the survival time of mice in the S20Y mouse neuroblastoma model, while high doses increase tumor diameter, shorten the latency period, and reduce survival time in this mouse model^[3].
Naltrexone (0.1 mg/kg; intravenous injection; once daily; for 50 consecutive days) reduces tumor incidence and prolongs the latency period in mice bearing HT-29 human colon cancer^[3].
Naltrexone reduces food intake in diet-induced obesity (DIO) mice and fasted lean mice, and exerts a synergistic effect when combined with Bupropion^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 16590-41-3
Appearance Solid
Molecular Weight 341.40
Formula C₂₀H₂₃NO₄
Color White to off-white
SMILES

OC1=CC=C2C3=C1O[C@](C(CC4)=O)([H])[C@@]3(CCN5CC6CC6)[C@]4(O)[C@@]5([H])C2
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (292.91 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9291 mL

14.6456 mL

29.2912 mL

5 mM

0.5858 mL

2.9291 mL

5.8582 mL

10 mM

0.2929 mL

1.4646 mL

2.9291 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (14.65 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lee B, et al. The uses of naltrexone in dermatologic conditions. J Am Acad Dermatol. 2019;80(6):1746-1752. [Content Brief]

[2]. Younger J, et al. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. [Content Brief]

[3]. Liubchenko K, et al. Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures. Adv Ther. 2021;38(2):904-924. [Content Brief]

[4]. Lobmaier PP, et al. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. CNS Neurosci Ther. 2011;17(6):629-636. [Content Brief]

[5]. Billes SK, et al. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1-11. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9291 mL	14.6456 mL	29.2912 mL	73.2279 mL
	5 mM	0.5858 mL	2.9291 mL	5.8582 mL	14.6456 mL
	10 mM	0.2929 mL	1.4646 mL	2.9291 mL	7.3228 mL
	15 mM	0.1953 mL	0.9764 mL	1.9527 mL	4.8819 mL
	20 mM	0.1465 mL	0.7323 mL	1.4646 mL	3.6614 mL
	25 mM	0.1172 mL	0.5858 mL	1.1716 mL	2.9291 mL
	30 mM	0.0976 mL	0.4882 mL	0.9764 mL	2.4409 mL
	40 mM	0.0732 mL	0.3661 mL	0.7323 mL	1.8307 mL
	50 mM	0.0586 mL	0.2929 mL	0.5858 mL	1.4646 mL
	60 mM	0.0488 mL	0.2441 mL	0.4882 mL	1.2205 mL
	80 mM	0.0366 mL	0.1831 mL	0.3661 mL	0.9153 mL
	100 mM	0.0293 mL	0.1465 mL	0.2929 mL	0.7323 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Naltrexone

All Opioid Receptor Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Naltrexone Related Classifications

Cat. No.: HY-76711